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ABSTRACT
Mercaptopurine (MP) is a cytotoxic thiopurine important for the
treatment of cancer and autoimmune diseases. MP and other
thiopurine drugs undergo extensive intracellular metabolism, but
themechanisms of action are poorly characterized. In particular, it
is unknown how different metabolites contribute to cytotoxicity
and incorporation of thiopurine bases into DNA. The aim of this
study was to ask whether cytotoxicity results from the incorpo-
ration of thioguanosine nucleotides into DNA, an alternative
thiopurine metabolite, or a combination of factors. Therefore, we
measured the cytotoxicity, metabolism, and incorporation of
thioguanosine into DNA in response to MP or MP metabolites.
Thiopurine metabolites varied in cytotoxicity, with methyl-
thioinosine-mono-phosphate and thioguanosine-tri-phosphate
the most toxic, and the methyl-thioguanosine nucleotides the
least. We show, using liquid chromatography-tandem mass
spectrometry, how different metabolites may perturb biochemical
pathways, particularly disrupting guanosine nucleotide homeo-
stasis, that may contribute to the mechanism of action of
thiopurines. Although there was no correlation between metabo-
lite cytotoxicity and the levels of 6-methylthioinosine-mono-
phosphate or thioguanosine incorporation into DNA as individual
factors, a combined analysis suggested that these factors to-
gether had a major influence on cytotoxicity. This study empha-
sizes the importance of enzymes of nucleotide homeostasis,
methylation, and demethylation in thiopurine effects. These
results will facilitate the development of dynamic biochemical
models of thiopurine biochemistry that will improve our under-
standing of mechanisms of action in relevant target tissues.
Introduction
The thiopurine drugs, azathioprine, mercaptopurine (MP), and
6-thioguanine have been used as immunosuppressants since the early
1950s for treatment of inflammatory bowel disease (IBD), childhood
acute lymphoblastic leukemia, autoimmune hepatitis, rheumatic disease,
and as a drug to reduce organ transplant rejection (Coulthard and
Hogarth, 2005; Fotoohi et al., 2010). Thiopurines are prodrugs and have
to be extensively metabolized to exert their cytotoxic effect. Azathio-
prine is non-enzymatically reduced to MP and an imidazole group. MP
and 6-thioguanine undergo metabolism before exerting cytotoxicity: both
drugs generate thioguanosine nucleotides via hypoxanthine guanine phos-
phoribosyltransferase (HPRT), but the metabolism of MP is more complex,
with a different range of metabolites compared with 6-thioguanine.
Deoxythioguanosine-tri-phosphate, a metabolite produced by MP or
6-thioguanine, is a substrate for DNA polymerases, and estimates of
steady-state levels of deoxythioguanosine (dTG) in DNA of patients
suggest that during replication between 0.01% and 0.1% of DNA
guanines (around 105–106 per cell) may be substituted by the thiobase
(Warren et al., 1995). In addition, MP or its metabolites can be
diverted from pathways of nucleotide incorporation by xanthine
oxidase-mediated inactivation to thiouric acid, or by thiopurine
methyltransferase (TPMT)-mediated methylation of thiopurine nu-
cleotides or thioinosine nucleotide precursors (Coulthard and
Hogarth, 2005; Fotoohi et al., 2010; Coulthard, 2012) (Fig. 1).
Several mechanisms of action have been elucidated to explain the
therapeutic mechanisms of thiopurines as immunosuppressants or antileu-
kemic drugs, and these include the inhibition of de novo purine synthesis
(DNPS) (Dervieux et al., 2001; Coulthard et al., 2002), alterations in DNA
methylation state via decreased levels of DNA (cytosine-5)-
methyltransferase 1 (DNMT1) (Coulthard et al., 2011), the disruption of
guanosine-tri-phosphate (GTP) signaling (Tiede et al., 2003), and in-
corporation of thioguanosine nucleotides as fraudulent bases into theDNA.
The latter causes DNA-protein crosslinks, single-strand breaks, interstrand
crosslinks, and sister chromatid exchanges (Maybaum and Mandel, 1981,
1983; Pan and Nelson, 1990), resulting in activation of the mismatch repair
Work contributing to this study was supported by a Biotechnology and
Biological Sciences Research Council studentship [DTA Systems Biology],
and grants from Newcastle Healthcare Charity, the JGW Patterson Foundation,
and the Medical Research Council [Confidence in Concept award; Grant reference
mc-pc-14101v.2].
https://doi.org/10.1124/dmd.118.081844.
s This article has supplemental material available at dmd.aspetjournals.org.
ABBREVIATIONS: DNPS, de novo purine synthesis; dTG, 6-thio-2-deoxyguanosine, deoxythioguanosine; dTGDNA, deoxythioguanosine in DNA; GTP,
guanosine-tri-phosphate; HPLC, high-performance liquid chromatography; meTGDP, 6-methylthioguanosine-di-phosphate; meTGMP, 6-methylthio-
guanosine-mono-phosphate; meTGTP, 6-methylthioguanosine-tri-phosphate; meTGXP, methyl-thioguanosine nucleoside phosphates; meTIMP,
6-methylthioinosine-mono-phosphate; meTITP, 6-methylthioinosine-tri-phosphate; MP, mercaptopurine; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; TGDP, 6-thioguanosine-di-phosphate; TGMP, 6-thioguanosine-mono-phosphate; TGTP,
6-thioguanosine-tri-phosphate; TGXP, thioguanosine nucleoside phosphates; TIDP, 6-thioinosine-di-phosphate; TIMP, 6-thioinosine-mono-phos-
phate; TITP, 6-thioinosine-tri-phosphate.
1191
http://dmd.aspetjournals.org/content/suppl/2018/06/08/dmd.118.081844.DC1
Supplemental material to this article can be found at: 
 at A
SPET Journals on July 13, 2018
dm
d.aspetjournals.org
D
ow
nloaded from
 
system (Swann et al., 1996) and induction of apoptosis. Furthermore, the
inhibition of Rac1 activation by the binding of TGTP instead of GTP to
Rac1 induces apoptosis via a mitochondrial pathway (Tiede et al., 2003).
Although therapeutic responses in leukemia correlate with levels of dTG
incorporation in target cells (Ebbesen et al., 2013), the relationships between
clinical outcome and other potential mechanisms of response such as Rac1
inhibition or DPNS are unknown, particularly for MP (or its precursor drug
azathioprine), which has greater metabolic complexity than 6-thioguanine.
Furthermore, in the context of immunosuppression, the amount of dTG in
DNA does not appear to be a biologic marker of clinical response in IBD
(Coulthard et al., 2017). Key issues for understanding the therapeutic
mechanisms of MP are: the contribution of different metabolites and their
rates of production to cytotoxicity and the incorporation of dTG into DNA,
and whether these are separable consequences of different pathways of MP
metabolism. These issues need to be addressed in an isogenic background to
avoid cell-specific variation in expression of enzymes or other cellular
characteristics that would otherwise confound interpretation. MP is used to
treat childhood acute lymphoblastic leukemia as part of maintenance
therapy; therefore, we employedMOLT-4 cells, a T-cell acute lymphoblastic
leukemia cell line, as an experimental model. For this proof-of-principle
study we developed a new liquid chromatography–mass spectrometry
(LS-MS/MS) method to investigate the metabolism of MP and its metab-
olites, and to test the link between cytotoxicity, thiopurine metabolites, and
incorporation of fraudulent bases into DNA.
Materials and Methods
Cell Culture. MOLT-4 (T-cell acute lymphoblastic leukemia cells, derived
from authenticated stocks in this institute) were maintained in RPMI
1640 (Sigma-Aldrich, Poole, UK) containing 10% fetal calf serum (Sigma-
Aldrich) at 37C, 5% CO2, and were tested for mycoplasma infection every
2 months. For viability assays, repeated on three separate occasions, cells were
seeded into 96-well plates at 2 103/100 ml and after 24 hours, serially diluted
thiopurine metabolites (a single metabolite per plate) were added to the cells;
cell viability was determined after 72 hours using the MTS assay (CellTiter
96 AQueous Assay; Promega, Southampton, UK) according to the manufac-
turer’s protocol.
Twelve thiopurine metabolites were commercially available (Jena Bioscience,
Jena, Germany): 6-thioguanosine-mono-phosphate (TGMP), 6-thioguanosine-di-
phosphate (TGDP), 6-thioguanosine-tri-phosphate (TGTP), 6-methylthioguanosine-
mono-phosphate (meTGMP), 6-methylthioguanosine-di-phosphate (meTGDP),
6-methylthioguanosine-tri-phosphate (meTGTP), 6-methylthioinosine-
mono-phosphate (meTIMP), 6-methylthioinosine-di-phosphate (meTIDP),
6-methylthioinosine-tri-phosphate (meTITP), 6-thioinosine-mono-phosphate
(TIMP), 6-thioinosine-di-phosphate (TIDP) and 6-thioinosine-tri-phosphate
(TITP). IUPAC names are given in Supplemental Information. For drug-
sensitivity assays, cells were exposed to each thiopurine metabolite individually
on three separate occasions for 72 hours (three-doubling times); this is the time
required for incorporation of thioguanosine nucleotides into the DNA of
replicating cells and the minimum exposure time to elicit cell death by
thiopurine drugs at the EC50 concentrations determined by the MTS assay.
The concentrations of MP used were similar to plasma concentrations (1.3 mM,
range 0.75–2.2 mM) in children with acute lymphoblastic leukemia treated with
standard doses of MP (100 mg/m2) (Estlin, 2001).
Fig. 1. Diagrammatic summary (center) of pathways of thiopurine
metabolism. Thionucleotide abbreviations are as used in the text;
MeMP, 6-methylmercaptopurine. Structures of thiopurine nucleo-
side mono-phosphates and the parent drug are shown in red boxes.
GMPS, Guanosine monophosphate synthetase EC 6.3.5.2;
HPRT, hypoxanthine-guanine phosphoribosyltransferase EC
2.4.2.8; IMPDH, inosine monophosphate dehydrogenase
EC 1.1.1.205; ITPase, inosine triphosphate pyrophosphatase
EC 3.6.1.9.
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Cell pellets for LC-MS/MS assays were generated by seedingMOLT-4 cells at
a density of 1.5 105/ml (total of 1.5 106) and thiopurine metabolites added to
the appropriate concentrations. After 72 hours, cells were pelleted by centrifu-
gation, resuspended, and washed twice in PBS to remove free external drug or
metabolites, and washed cell pellets stored at 280C prior to extraction for
analysis by LC-MS/MS. Pellets were generated for all metabolite-treated and
control (no metabolite) cells in three independent experiments.
Sample Preparation for LC-MS/MS Assay of Deoxythioguanosine in
DNA. Cell pellets were resuspended in 350 ml of buffer B (400 mM Tris, 60 mM
EDTA, 150mMNaCl) and 90ml of 5M sodium perchlorate. Samplesweremixed
at room temperature for 10 minutes, or until the pellet was completely dissolved,
after which they were incubated at 65C for 45 minutes. An equal volume of
chloroform was added to each sample and mixed for 20 minutes at room
temperature, followed by centrifugation at 432g for 10 minutes at 4C. The top
layer was then removed and DNA precipitated by addition of 2.5 volumes of
ethanol, and samples centrifuged at 16,000g. Precipitated DNA was resuspended
in 5 mM of Tris-HCl, pH 8, by incubation overnight at 50C.
Analysis of deoxythioguanosine in DNA (dTGDNA) used a previously
published method (Coulthard et al., 2016). In outline, DNA was diluted to 0.2
mg/ml in a total volume of 100 ml of 1 mM 6-(Methylthio)-9H-purine-d3 and
denatured by heating to 100C for 5 minutes. After being chilled on ice for
2 minutes, 10ml of 10 digestion buffer (500 mM sodium acetate, 10mMMgCl2
pH5.3) and 5 ml of 0.12 IU/ml nuclease P1 was added and incubated for 1 hour at
50C. Finally, 20 ml Tris-HCl and 1 ml of alkaline phosphatase (1 IU/ml) were
added to each sample, incubated for 30 minutes at 40C, and samples then diluted
either 1/10 or 1/100 for analysis by LC-MS/MS.
Sample Preparation for LC-MS/MS Assay of Cytosolic Thiopurine
Metabolites. MOLT-4 cell pellets were defrosted on ice and ice-cold propanol
(200 ml) immediately added. Propanol was evaporated from the cells using a
TurboVap LV automated evaporation system (Biotage, Hengoed, UK) with
nitrogen gas (5 psi). Once completely dry, 200 ml of deionized water was added,
samples vortexed, and centrifuged 16,000g for 10 minutes. The supernatant was
transferred into a high-performance liquid chromatography (HPLC) glass insert
for subsequent LC-MS/MS analysis.
LC-MS/MS and Reagents. The thiopurine metabolite standards, as listed
above, were from Jena Bioscience. 6-Thio-2-deoxyguanosine standard (deoxy-
thioguanosine; dTG) was from Carbosynth (Compton, UK). 6-(Methylthio)-9H-
purine-d3 was from Toronto Research Chemicals Inc. (Toronto, Canada). HPLC
grade acetic acid was from Fisher Scientific (Loughborough, UK). Lymphoprep
was from Axis-Shield and Pierce BCA kit was from Thermo Fisher Scientific
(Cramlington, UK). All other reagents were from Sigma-Aldrich. Chromato-
graphic separations were performed with a Shimadzu Prominence UFLC
(Shimadzu, Kyoto, Japan).
An API4000 triple quadrupole MS/MS (Applied Biosystems, Foster City, CA)
was used for analysis with electrospray ionization (ESI) performed in positive ion
mode using nitrogen gas. Optimization of MS/MS parameters for all analytes was
performed by selecting precursor ions and determining the most prominent four
product ions. The three best were then further optimized for fragmentation and
voltage parameters until the most abundant and robust product ion could be
ascertained. Quantification of analytes was performed in multiple reaction
monitoring (MRM) mode: mass transitions and optimized MS/MS parameters are
given in Supplemental Table 1 and validationmethods in Supplemental Information
and Supplemental Table 2. Analyst software v1.5 (SCIEX, Framingham, MA) was
used for sample analysis, peak integration and analyte quantification.
LC-MS/MS Analysis of Cytosolic Thiopurine Metabolites. Chromato-
graphic separation of thiopurine metabolites was achieved using a Clarity Oligo-
WAX column (150  4.6 mm) and SecurityGuard Oligo-WAX guard column
(4 3 mm) both from Phenomenex (Cheshire, UK) maintained at 30C. Analytes
were eluted with mobile phases of 0.01M aqueous ammonium acetate pH 8.0 (A)
and 0.01 M aqueous ammonium acetate pH 10.01 (B). The mobile phase system
consisted of a starting condition at 90% A followed by a 0.5 minute gradient from
90% A to 80% A at 1.5 minutes. A 2 minute gradient from 80% A to 0% A was
carried out at 3.5 minutes with those conditions maintained until 13.5 minutes
when the column was returned to 10% A in a 0.5 minute gradient. The flow rate
was 0.7 ml/min and a post-column flow splitter was used to divert 70% of mobile
phase to waste and improve ionization. Standards and samples were injected in a
volume of 50 ml. Standards were freshly diluted from a secondary dilution of
Fig. 2. LC-MS/MS profiles for thiopurine nucleoside phosphates in standard
mixtures and MOLT-4 cell extracts (samples), where X indicates mono-, di-, or
tri-phosphate. For each plot in (A–F) dotted lines represent the monophosphates,
solid lines represent the diphosphates, and dashed lines represent the triphos-
phates [legend in (A)]. (A) Methyl-thioinosine nucleoside phosphate (meTIXP)
standards; (B) thioguanosine nucleoside phosphate (TGXP) standards; (C) methyl-
thioguanosine nucleoside phosphate (meTGXP) standards; (D) MOLT-4 cell extract
(sample) analyzed for meTIXPs; (E) MOLT-4 cell extract analyzed for TGXPs;
(F) MOLT-4 cell extract analyzed for meTGXPs; in this trace, the identities of
additional peaks that were not eluted at the retention times of the standards are
unknown. Ordinate scales are arbitrary intensity units.
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stock on the day of analysis, and the secondary dilutions were used within
6 months of preparation from the primary stocks received from the manufacturer;
the standards were stable under this protocol. Optimum settings for MS/MS
detection were: curtain gas, 10; ion source gas 1, 40; ion source gas 2, 50;
ion spray voltage, 5500; collision gas, 6; entrance potential, 10; ionization
temperature, 400C. Examples of LC-MS/MS profiles for standards and samples
are shown in Fig. 2.
LC-MS/MS Analysis of Deoxythioguanosine in DNA. Chromatographic
separation of dTG and deoxyadenosine from P1 nuclease digestion of DNA was
achieved using a XSelect HSS T3 3.5 mm 4.6  100 mm (Waters) XSelect HSS
T3, a VanGuard Cart 3.5 mm 3.9 5 mm guard column maintained at 30C, and
mobile phases of aqueous 0.05% formic acid and 0.05% formic acid in acetonitrile
(Coulthard et al., 2016). Standards were prepared from stock solutions of 100 mg/ml
deoxyadenosine and 2000 ng/ml dTG; standards and samples were injected in a
volume of 50 ml (Coulthard et al., 2016). Two standard curves and three sets of
controls for each metabolite were included in each assay.
In Silico Modeling. Interconversion between thioguanosine nucleoside mono-,
di-, and tri-phosphates was modeled using the biochemical simulation software
CoPaSi version 4.12 (Hoops et al., 2006). Rate constants, based on values in the
BRENDA enzyme database (www.brenda-enzymes.org) (Placzek et al., 2017),
were fixed and rate values (V) for rate equations in the model fitted to
experimental data.
Data Analysis. Viability data were obtained in three separate experiments for
each compound. Data were blank (medium but no cells) corrected and expressed
as a proportion of control cells treated with vehicle only. Mixed-effects models to
account for random differences between experiments were used to estimate the
mean and S.E. for the upper asymptote, slope and EC50 from three-parameter
logistic curves with the “nlme” package in R version 3.1.2 (R Core Team, 2016).
EC50 was defined with respect to the maximum and minimum of the logistic
curves rather than the viability of untreated control cells; some of the compounds
showed hormetic effects by increasing cell growth (viability) at low doses and this
was reflected by fitted upper asymptotes.100% of control. To avoid over-fitting,
the lower asymptotewas fixed at zero for data where viability was approaching zero
but the lower asymptote was just outside the data range, but otherwise was fixed on
estimates obtained from a four-parameter curve fit with all data using package “drc”
in R (Ritz et al., 2015). For two drugs where mixed-effects fits did not converge
to a solution, four-parameter logistic curves were fitted to each experiment using
drc and the mean of separate EC50 values calculated. Data are expressed as means
6 S.E.M. Partial correlation and principal components analyses were carried out
using the R packages “ppcor” and “FactoMineR,” respectively.
Results
Cytotoxicity of Thiopurine Metabolites
To assess the cytotoxicity of individual thiopurine metabolites, an
extended incubation time of 72 hours, representing approximately three
cell doublings, was used to assess the effects on cell viability. This
timescale was also used for assessing the role of dTG incorporation into
DNA as a mechanism of cytotoxicity of the parent thiopurine drug or its
metabolites. After incubation with cells for 72 hours, the parent drug,
MP, had an EC50 of the order of 3 mM (Fig. 3; Table 1). With the
exception of the thioinosine di- and tri-phosphates and the methylated
thioguanosine nucleotides, MP metabolites were more toxic, with EC50
values ranging from 0.6 to ,0.2 mM. The thioguanosine nucleotides
varied in cytotoxicity with TGTP the most toxic (EC50 0.265 mM) and
TGMP the least (EC50 0.619 mM). The methylated thioguanosine
nucleotides had the lowest toxicities of all, in spite of being able to enter
cells (see below), and only meTGTP elicited a cellular response, albeit at
a very high concentration (EC50 15.37 mM). TIMP is a direct derivative
Fig. 3. Viability curves for MOLT-4 cells treated for 72 hours with MP or
thiopurine metabolites: (A) MP (solid black line, m), TGMP (dotted black line, ♦),
TGDP (solid gray line, u, gray fill), TGTP (dashed black line, d); (B) meTIMP
(dotted black line, ♦), meTIDP (solid gray line, u, gray fill), meTITP (dashed black
line, d), meTGDP (solid black line, m); (C) TIMP (dotted black line, ♦), TIDP
(solid gray line, u, gray fill), TITP (dashed black line, d).
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of the parent drug, 6-MP, via HPRT and had a relatively high cytotoxicity
comparable to TGTP, but this was increased by methylation as meTIMP
had the highest cytotoxicity of all the metabolites tested (EC50 0.185 mM;
Table 1). Methylation also doubled the cytotoxicity of TITP but only had a
small effect on cytotoxicity of TIDP (Table 1).
Metabolism of Mercaptopurine Metabolites
MP and Thioguanosine Nucleoside Phosphate Metabolites. Cells
were incubated with MP or individual metabolites at their EC50
concentrations for 72 hours before LC-MS/MS analysis of intracellular
metabolite levels. TIMP, TIDP, and TITPwere not measured as there was
no separation by LC and the major ions detected by MS/MS were the
same for each compound. After incubation with MP, meTIMP was the
major cellular metabolite, together with residual amounts of parent drug.
Thioguanosine nucleoside phosphates were present at lower levels, with
TGMP the most abundant and lower levels of TGDP and TGTP (Fig. 4).
For cells incubated with thioguanosine nucleoside phosphates, treatment
with either TGMP or TGDP produced similar distributions of all three
thioguanosine phosphates, with TGDP predominating in both cases; the
methylated equivalents had similar profiles but at levels one-fifth or lower
of the unmethylated thioguanosine nucleotides (Fig. 4). Conversely, in
cells incubated with TGTP, the profile of thioguanosine nucleotides
differed markedly, with TGMP in greatest abundance and substantially
lower levels of TGDP and the parent TGTP. Cells treated with MP had a
distribution of thioguanosine nucleoside phosphates substantially biased
toward TGMP similar to TGTP-treated cells, (Fig. 4, A and B).
To provide insight into potential mechanisms underlying differences in
thioguanosine nucleotide profiles between cells treated with TGTP, and
either TGMPor TGDP, steady-state thioguanosine nucleotide levels were
modeled as a simple network of the three thioguanosine nucleotides in a
closed system with enzyme activity representing guanylate kinase,
nucleotide diphosphate kinase, GTPase, ATP apyrase (acting on TGTP),
and guanosine diphosphatase (Fig. 4C). At steady-state, an initial model
was a good fit to experimental data for cells treated with TGMP or TGDP
with respect to the proportions of thioguanosine nucleotides but not for
the experimental data for cells treated with TGTP. Refitting the model
separately to experimental data for TGTP-treated cells showed that a
16-fold increase in guanosine diphosphatase activity would be sufficient
to account for the thioguanosine nucleotide profile observed for cells
treated with TGTP (Fig. 4D).
Methyl-Thioguanosine Nucleoside Phosphate Metabolites. Treat-
ment of cells with meTGMP resulted in some demethylation to TGMP
after 3 days, and some possible conversion to lower levels of meTGDP
TABLE 1
Effects of individual metabolites on MOLT-4 cell viability
Data are listed in order of decreasing cytotoxicity. Model fitted: mmixed-effects; xmean from
separate curves.
Drug EC50 (mM) S.E.
meTIMP 0.185 0.026m
TGTP 0.265 0.076x
TIMP 0.345 0.055m
TGDP 0.360 0.104m
meTIDP 0.393 0.085m
meTITP 0.396 0.039x
TIDP 0.412 0.097m
TGMP 0.619 0.051m
TITP 0.956 0.214m
MP 2.92 0.415m
meTGTP 15.37 3.556m
meTGDP .2000 ND
meTGMP .2000 ND
ND, compounds not toxic and EC50 could not be estimated.
Fig. 4. Metabolites present in cells after incubation for 72 hours
with MP or thiopurine nucleotides at the EC50 for cell toxicity
(Table 1) and measurement by LC-MS/MS. Color is used to
designate the drug used for cell treatment (specified in the
legends), with bars for each drug reflecting the mean (6 S.E.)
concentration of the drug or its metabolites extracted from the
cells. (A) MOLT4 cells treated with MP or each thioguanosine
nucleoside tri-phosphate; (B) data in (A) on an expanded scale
to clarify intracellular thioguanosine nucleoside levels; (C) a
simple nucleotide model of thioguanosine nucleoside phosphate
homeostasis. Km values (mM) for Henri-Michaelis-Menten
irreversible kinetics were fixed at: guanylate kinase (EC 2.7.4.8:
15), GTPase (100), ATP apyrase (EC 3.6.1.5: 78), guanosine
diphosphatase (EC 3.6.1.42: 100). Nucleoside diphosphate
kinase activity (EC 2.7.4.6) was modeled with fixed mass
action kinetics, setting k (forward and reverse) as 24 minutes21.
(D) Fitting rate values (V) to data using the model in C gave
rate values (mM min21) for guanylate kinase (1578.4), GTPase
(3129), ATP apyrase (15), guanosine diphosphatase (8914) and
the steady-state ratios of thioguanosine nucleoside phosphates
indicated by black bars. A 16-fold increase in rate values (V) for
guanosine diphosphatase was sufficient to reproduce experimental
data for TGTP treatment (gray bars).
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and meTGTP, giving a distribution similar to the unmethylated
thioguanosine nucleotides in Fig. 4, A and B. Conversely, meTGDP
was converted mainly to meTGMP. For cells treated with meTGTP,
there was substantial dephosphorylation to meTGMP and demethylation
to TGMP with TGMP the main metabolite remaining (Fig. 5A), and a
similar distribution of methylated thioguanosine nucleoside phosphates
to the unmethylated equivalents (Fig. 4, A and B). Thus, both de-
phosphorylation and demethylation reactions are involved in the metab-
olism of the methylated thioguanosine nucleoside phosphates.
Thioinosine and Methyl-Thioinosine Nucleoside Phosphate
Metabolites. After incubation with TIMP, there was substantial meth-
ylation to meTIMP; TIMP was also metabolized to TGMP and low
levels of methylated thioguanosine nucleotides were also produced
(Fig. 5B), as would be predicted from known biochemical pathways. For
TIDP and TITP, in contrast to TIMP, there was very little conversion
to meTIMP and only very small amounts of TGMP were detectable
(Fig. 5B).
MeTIMP was the major metabolite after incubation with meTIMP,
meTITP, or meTIDP with no other metabolites detectable other than low
levels of residual treatment metabolite (Fig. 5C). The presence of low
levels of meTIDP and meTITP after treatment with meTIMP may
represent low-level contaminants of #3% in the commercial source of
meTIMP used; these compounds were not detectable above background
at the concentrations of meTIMP analytical standards used. The results
show that meTIDP and meTITP were efficiently dephosphorylated to
meTIMP but without evidence for demethylation. Although meTIMP
was the most toxic metabolite in viability assays, there was no
correlation between metabolite EC50 in viability assays (Table 1) and
the levels of meTIMP produced from each metabolite in treated cells
(Spearman rank correlation, P = 0.2873).
Incorporation of Thioguanosine Nucleotides into DNA
In separate experiments, MOLT4 cells were treated with parent
drug or each of the metabolites (except TIDP and TITP; Fig. 6) at
EC50 concentrations for 72 hours and DNA extracted for assay of
dTG. DNA-incorporated dTG was detectable significantly above
background (ANOVA, Dunnett post-hoc test, P , 0.05; Fig. 6)
only in cells treated with MP (P, 0.001), TGDP (P, 0.001), TGTP
(P = 0.03), or TIMP (P = 0.006). There was no significant correlation
between dTGDNA and metabolite EC50 in viability assays (Spearman
rank correlation, P = 0.3614). Apart from the low dTGDNA after
TGMP treatment, these results confirm the expected route of in-
corporation of thioguanosine metabolites of MP into DNA via TIMP,
TGDP, and TGTP, and show that meTIMP cytotoxicity was in-
dependent of dTGDNA.
Data Integration
The data for cytotoxicity (EC50) to different metabolites, dTG
DNA,
and metabolite levels after treatment of cells with different metabolites
for 72 hours were summarized using partial correlation and principal-
components analyses. To reduce the number of variables, measurements
of mono-, di-, and tri-phosphates were combined to give thioguanosine
nucleoside phosphates (TGXP), methyl-thioguanosine nucleoside phos-
phates (meTGXP), and methyl-thioinosine nucleoside phosphates
(meTIXP). There was a significant partial correlation between TGXP
Fig. 5. Metabolites present in cells after incubation for 72 hours with thiopurine
nucleoside phosphates at the EC50 for cell toxicity (Table 1) and measurement by
LC-MS/MS. Color is used to designate the drug used for cell treatment (specified in the
legends), with bars for each drug reflecting the mean (6 S.E.) concentration of each drug
metabolite extracted from the cells. (A) MOLT4 cells treated with methyl-thioguanosine
nucleoside phosphates (methyl-TGXPs,); (B) MOLT4 cells treated with thioinosine
nucleoside phosphates (TIXPs, where X represents mono-, di-, or tri-phosphate); (C)
MOLT4 cells treated with methyl-thioinosine nucleoside phosphates (methyl-TIXPs).
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and meTGXP (P = 0.005), as might be predicted; the partial correlation
between dTGDNA and TGXP approached significance (P = 0.065) and
such a relationship would also be expected. However, there were no
significant partial correlations between EC50 and either dTG
DNA or
thioguanosine metabolites (P. 0.1). In a principal component analysis
of dTGDNA and thioguanosine metabolites as independent variables,
74% and 18% of the variance was accounted for by two principal
components (PC1 and PC2, respectively; Supplemental Table 3). PC1
had major contributions from dTGDNA, TGXP, and meTGXP, whereas
meTIXP was the dominant component (82.7%) of PC2 (Table 2), with a
small contribution from dTGDNA (13.6%). There was no significant cor-
relation of EC50 with PC1 (P . 0.5; Pearson correlation coefficient =
20.24; t8 = 20.66), but the correlation between EC50 and PC2
approached significance (P = 0.059; Pearson correlation coefficient =
20.62; t8= 22.21), suggesting that methyl-thioinosine nucleoside
phosphates might be key drivers of cell toxicity.
Discussion
Although in the past many studies of the biochemistry of thiopurines
have focused on red blood cells, such studies will not capture the
complexity of biologic responses to MP in nucleated cells, the bio-
logic targets for thiopurine therapy (Duley and Florin, 2005). Reliable
measurement of thiopurine metabolites in isolated blast cells from
leukemic patients is notoriously difficult as exemplified by the paucity
of published methods. A relevant in vitro model is important for
the development of appropriate analytical methods for elucidating
the contribution of different thiopurine metabolites to cytotoxicity and
the mechanism of action of MP. In this respect, the present study is
unique in assessing how thiopurine cytotoxicity and incorporation of
fraudulent bases into DNA is related to the levels of different thiopurine
metabolites.
The results emphasize that the cytotoxicity of thiopurines on nucleated
cells will be combinatorial effects of different mechanisms. The in-
corporation of thioguanosine nucleotides into DNA promotes cell-cycle
arrest (Karran, 2006) and increases the chance of DNA strand breaks
(Fairchild et al., 1986; Lennard, 1992). These effects will account for
some of the cytotoxicity of MP and metabolites such as TGDP. Overall,
the incorporation of dTG into DNA may be a minor mechanism of
cytotoxicity in MOLT4 cells. Recent studies have failed to find a good
correlation between dTG incorporation into DNA and clinical efficacy as
immunosuppressants (Coulthard et al., 2016, 2017), but the converse has
been established for acute lymphoblastic leukemia (Nielsen et al., 2017).
However, it is important to recognize the very different contexts of
disease biology between uses of thiopurines as anticancer drugs versus
thiopurines as immune system modulators.
MP can exert a cytotoxic effect in cells with high levels of TPMT
without measurable levels of dTGDNA (Coulthard et al., 2002), and our
analyses of thiopurine metabolites after treating cells with the parent drug
or its knownmetabolites highlight perturbations to biochemical pathways
that may underlie alternative mechanisms of cytotoxicity, even for
leukemia cells in vitro. LC-MS/MS data show that all metabolites were
able to enter the cells, and for simplicity in interpretation we assume
comparable rate constants.
MeTIMP was the most toxic metabolite in viability assays and was the
major metabolite in MP-treated cells after 72 hours. There was no
evidence for metabolism of meTIMP to thioguanosine nucleotides for
incorporation into DNA, or evidence of demethylation to other thio-
nucleotide metabolites. From other studies there is direct evidence that
meTIMP is an inhibitor of phosphoribosyl pyrophosphate amidotransfer-
ase (Tay et al., 1969; Vogt et al., 1993) and will reduce cell viability as a
consequence of the inhibition of DNPS (Coulthard et al., 2002, 2011) and
decreased RNA synthesis. Inhibition of DNPSwill increase incorporation
of dTG into DNA as a consequence of a reduction in the endogenous
nucleotide pool (Bokkerink et al., 1993; Ebbesen et al., 2013); therefore,
inhibition of DNPS via meTIMP in MOLT4 cells will be a substantial
factor in the cytotoxic effects of MP, necessitating reliance on the
nucleotide salvage pathway to sustain DNA replication (Coulthard et al.,
2011). MOLT4 cells express the enzyme methylthioadenosine phos-
phorylase (Yu et al., 1997), an enzyme required for the salvage of adenine
and methionine, but cells in which the MTAP gene is deleted are more
sensitive to MeTIMP because they lack the ability to ameliorate the
effects of DNPS inhibition via nucleotide salvage (Coulthard et al.,
2011). The purine salvage pathway has relatively low activity in
lymphoblasts (Bokkerink et al., 1993) and meTIMP as a major MP
metabolite probably plays a clinical role in reducing levels of
endogenous nucleotides, therefore enhancing the incorporation of dTG
into DNA (Hedeland et al., 2010; Ebbesen et al., 2013). MeTIMP also
contributes to a decrease in DNA methyltransferase levels and global
demethylation (Hogarth et al., 2008).
Fig. 6. Levels of deoxythioguanosine (dTG) incorporated into DNA (moles dTG
per 1000 moles of deoxyadenosine [dA]) of MOLT4 cells after culture with
equitoxic doses of thiopurine metabolites. Metabolites were used at their EC50
concentrations (Table 1) and the cells cultured for 72 hours before extraction and
analysis. Bars are arranged, left to right, in order of decreasing cytotoxicity as given
in Table 1. TIDP and TITP were not included in these experiments as they would be
expected to contribute only by dephosphorylation to TIMP. Values were compared
by ANOVA to the control (MOLT4 cells without thiopurine; c) with Dunnett post-
hoc test; error bars were derived from ANOVA and statistical significance compared
with the background control (no thiopurine treatment) is indicated by: *P , 0.05;
**P , 0.01; ***P , 0.001.
TABLE 2
Contributions (%) of variables to principal components (PC)
Variable PC1 PC2 PC3 PC4
DNA 24.9 13.6 56.77 4.7
TGXP 32.02 2.9 5.55 59.5
meTGXP 30.05 0.76 33.43 35.76
meTIXP 13.04 82.7 4.25 1.97
meTIXP, methyl-thioinosine nucleoside phosphates.
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The amounts of meTIDP and meTITP detected as MP metabolites
were very low compared with meTIMP, and were also low in cells
treated with these methylthioinosine nucleotides, indicating effective
dephosphorylation to meTIMP and suggesting that the in vitro cytotox-
icity of these compounds resulted from conversion to meTIMP.
Although it has been stated that TITP is a substrate for TPMT (Stocco
et al., 2009; Seinen et al., 2013), the evidence on which this claim is
based is not clear and in our study there was no indication of substantial
methylation of TIDP or TITP. Bearing in mind that TIXPs were not
measured, there was no evidence that meTIMP was demethylated to
TIMP leading to thioguanosine nucleoside phosphate synthesis. With
respect to the thioinosine nucleoside phosphates, TIMP was the most
cytotoxic presumably as a result of methylation to meTIMP but with a
contribution from dTGDNA via metabolism to TGMP.
In addition to meTIMP, MP was metabolized to the three thiogua-
nosine nucleoside phosphates, with TGMP in excess over TGDP and
TGTP, a pattern also produced by treating cells with TGTP but not
TGDP or TGMP. A higher level of guanosine diphosphatase activity in
response to TGTP orMP compared with TGDP or TGMP could account
for the comparative effects of the different thioguanosine nucleoside
phosphates in these experiments. However, the ratios of thioguanosine
nucleotides in treated cells were markedly different from an expectation
on the basis of the endogenous distribution of guanosine nucleotides in
normal cells, where guanosine-tri-phosphate would normally be in a
;10-fold excess over the mono- and di-phosphates (Traut, 1994). With
reference to a simple dynamic model of the three thioguanosine
nucleoside phosphates (Fig. 4C), this implies a substantial reduction in
guanylate kinase and nucleoside diphosphate kinase activities inMOLT-
4 cells as a result of MP or thioguanosine nucleotide treatment,
accompanied in MP- or TGTP-treated cells by a possible induction of
guanosine diphosphatase activity. Thus, changes in endogenous guano-
sine nucleotide homeostasis, potentially with substantial reductions in
endogenous GTP levels as a result of thioguanosine nucleotide-mediated
changes in enzyme activities, could be responsible for the inhibition of
Rac1 signaling leading to apoptosis in mercaptopurine-treated cells
(Tiede et al., 2003). This is an area of substantial importance for future
investigation.
The thioguanosine nucleoside phosphates were all present as
methylated and unmethylated metabolites. MeTGMP is 12-fold less
potent than meTIMP as a DNPS inhibitor (Allan and Bennett, 1971), but
all three methylated thioguanosine nucleotides had substantially less
cytotoxicity that their unmethylated equivalents. Therefore, methylation
of thioguanosine nucleoside phosphates via TPMT is an effective
mechanism for reducing the toxicities of these metabolites. In contrast to
the lack of evidence for demethylation of methylthioinosine nucleotides,
there was clear evidence for demethylation of meTGMP. Most of
the meTGDP and meTGTP ended up as either meTGMP or TGMP,
consistent with effective demethylation and guanosine diphosphatase
activity. There are few studies on the demethylation of meTGMP other
than in the context of DNA, but in view of the in vitro evidence, this
needs to be considered as a biologically relevant activity.
All the thioguanosine nucleoside phosphates resulted in dTGDNA in
treated cells, although this was not significantly above background with
TGMP, and was greatest with TGDP, as would be expected from the role
of GDP as a precursor for dGTP synthesis for DNA replication (Traut,
1994). However, other mechanisms of cytotoxicity are clearly involved
as TGTP was the most cytotoxic despite the lower dTG incorporation
into DNA compared with TGDP. This greater cytotoxicity could result
from greater disruption to Rac1 signaling implied by the lower levels of
TGTP in TGTP-treated cells.
The lack of correlation between the cytotoxicity of different
thiopurine metabolites and the meTIMP or dTGDNA produced by
cellular metabolism implies that at least three mechanisms may
contribute to the biologic activity of MP: meTIMP cytotoxicity by
inhibition of DNPS or other cellular functions, reduction in viability
as a result of dTG incorporation into DNA, and inhibition of GTP
signaling by changes in enzymes important for GTP homeostasis.
This is supported by the principal components analysis, which
highlights the strong contribution of methylthioinosine nucleoside
phosphates to cytotoxicity in combination with dTGDNA in MOLT4
cells. With respect to the parent drug, cell-, tissue-, and individual-
specific variations in TPMT expression and activity, dependence on
DNPS, the status of GTP homeostasis, DNA repair capacity, and the
rates of drug and metabolite efflux (Wielinga et al., 2002) will all affect
the contributions of different mechanisms to biologic effects. These
mechanisms are amenable, with the availability of sufficient biochemical
information, to modeling individually with integration into cell behavior
models, an approach which will facilitate improvements in the clinical
use and efficacy of thiopurine drugs. Such an approach would benefit
by a deeper understanding of the biochemical pathways of thiopurine
metabolism. This study emphasizes the importance of enzymes of
nucleotide homeostasis, methylation, and demethylation in those
pathways and will facilitate the development of dynamic biochemical
models of thiopurine biochemistry.
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